Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Barbara Burtness MD
Barbara Burtness MD Advisory Board
Guru Sonpavde MD
Guru P. Sonpavde MD Advisory Board
Jean-Yves Douillard MD, PhD
Jean-Yves Douillard MD, PhD Advisory Board
See All Experts
featured
Published in Oncology

Journal Scan / Research · October 10, 2024

Safety and Clinical Activity of Dual Androgen Receptor Degrader and Antagonist BMS-986365 in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer

Annals of Oncology

 

 Save  Recommend
 Share

Additional Info

Annals of Oncology
Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer
Ann. Oncol 2024 Sep 10;[EPub Ahead of Print], D Rathkopf, MR Patel, AD Choudhury, D Rasco, N Lakhani, JE Hawley, S Srinivas, A Aparicio, V Narayan, KD Runcie, H Emamekhoo, ZR Reichert, MH Nguyen, AL Wells, R Kandimalla, C Liu, S Suryawanshi, J Han, J Wu, VK Arora, M Pourdehnad, AJ Armstrong

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading

Most Read This Week

Recently Updated